Medical inquiries

Connect with my medical science liaison

Chat live

Available Monday - Friday 9AM - 4:30PM ET

Call me now

Available Monday - Friday 9AM - 7:30PM ET

Email your inquiry

Call 1-800-526-7736

Available Monday - Friday 9AM - 8PM ET

Live video

Available Monday - Friday 9AM - 4:30PM ET

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)

Medical Information

+ Save link

Dosage and Administration of DARZALEX FASPRO – Alternative Dosing Intervals

Last Updated: 10/03/2024

SUMMARY

Janssen cannot recommend any practices, procedures, or dosing modifications that deviate from the product labeling and are not approved by the regulatory agencies.
There are no systematically collected data to support alternative dosing intervals of DARZALEX FASPRO.
Clinical judgment should be exercised when considering any dosing interval adjustments outside of those listed in the DARZALEX FASPRO product labeling.
Review local labeling for approved dosing guidance.

Literature Search

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File databases (and/or other resources, including internal/external databases) was conducted on 01 October 2024.